Alleviating tumor hypoxia with perfluorocarbon-based oxygen carriers

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Hypoxia, a common challenge in cancer treatment, limits the efficacy of oxygen-dependent therapies like radiotherapy and photodynamic therapy.
• Perfluorocarbons (PFCs) are inert, oxygen-carrying liquids with potential applications in alleviating tumor hypoxia.
• PFC nanoemulsions and nanodroplets can deliver oxygen to tumor tissues and prolong the lifetime of reactive oxygen species.

Purpose of the Study:

• To review the literature on perfluorocarbon-based oxygen carriers for enhancing cancer treatment efficacy.
• To explore the potential of PFCs in improving radiotherapy, photodynamic therapy, and chemotherapy.
• To discuss the role of PFC carriers in promoting T-cell trafficking and enhancing anti-tumor immune responses.

Main Methods:

• Review of recent scientific literature on PFC-based oxygen delivery systems for cancer therapy.
• Analysis of PFC nanoemulsions, nanodroplets, and microbubbles for oxygen transport and release.
• Evaluation of PFC carrier functionalization for theranostic applications and immune modulation.

Main Results:

• PFC nanoemulsions effectively deliver oxygen to hypoxic tumors, enhancing the generation of tumoricidal reactive oxygen species.
• PFCs stabilize oxygen, expanding the lifetime of singlet oxygen (¹O₂) and improving therapeutic outcomes.
• Functionalized PFC nanocarriers offer versatile platforms for image-guided theranostics and targeted drug delivery.

Conclusions:

• Perfluorocarbon-based oxygen carriers represent a promising strategy to overcome tumor hypoxia and enhance the efficacy of various cancer treatments.
• PFCs can be engineered into sophisticated nanocarriers for multimodal cancer therapy, including chemotherapy, radiotherapy, and immunotherapy.
• Further research into PFC-based carriers may unlock novel approaches to improve anti-tumor immunity by facilitating T-cell infiltration.